Plain-English Summary
Semaglutide AUD EHR studied semaglutide in Large EHR cohorts of patients with obesity or type 2 diabetes. Semaglutide was associated with lower risk of incident and recurrent AUD diagnosis compared with non-GLP-1RA medications.
VV Study Evidence Matrix v1.0
VV Evidence Utility Score
A bounded score for how useful this study is in public explanation, based on evidence tier, design, applicability, endpoint relevance, limitations, safety signals, and publication/source strength.
63/100
Limited Public Evidence
- Evidence tier
- 66/100, weight 18%
- Design strength
- 66/100, weight 18%
- Applicability
- 75/100, weight 16%
- Endpoint relevance
- 35/100, weight 16%
- Limitations transparency
- 70/100, weight 12%
- Safety signal usefulness
- 45/100, weight 10%
- Publication/source strength
- 88/100, weight 10%
Useful for context, but limited by endpoint relevance, safety signal usefulness, evidence tier.
How the study framework works ->Key Findings
- Semaglutide was associated with lower risk of incident and recurrent AUD diagnosis compared with non-GLP-1RA medications.
- Findings were replicated across obesity and type 2 diabetes populations.
Limitations
- Observational design cannot prove causality.
- Outcome was medical diagnosis/encounter data, not direct measured alcohol consumption.
- Residual confounding is possible.
Why It Matters
Semaglutide was associated with lower risk of incident and recurrent AUD diagnosis compared with non-GLP-1RA medications.
Viral Vitalism Verdict
Useful evidence, bounded by design: Observational design cannot prove causality.
Sources
Signal cards
Used in signals
Signal coverage connected to this study through explicit study links, canonical source refs, or evidence visualizations.
GLP-1s, Dopamine, and Addiction: The Substance Use Signal
GLP-1 medications may do more than reduce appetite for food. Early clinical trials, real-world data, and preclinical research suggest they may also affect craving, reward, alcohol intake, and substance-use patterns - but the science is still developing.
VV Signal Score
57
Early or context-dependent
- Sources
- 19
- Studies
- 8
- Claims
- 3
Claim ledger
Relevant claims
Claim ledger records connected through this study's ID, topic tags, or source IDs.
glp 1: Semaglutide and tirzepatide should not be collapsed into one
Semaglutide and tirzepatide should not be collapsed into one generic claim because their mechanisms, labels, trial programs, and outcome evidence differ.
glp 1: Early randomized human studies suggest GLP-1 receptor agonists may
Early randomized human studies suggest GLP-1 receptor agonists may reduce some alcohol craving or drinking outcomes, but the evidence is not yet sufficient for routine addiction treatment.
glp 1: FDA-approved GLP-1 products and compounded, unapproved, or falsely labeled
FDA-approved GLP-1 products and compounded, unapproved, or falsely labeled products are different regulatory and quality-risk categories.
semaglutide: Semaglutide reduced major adverse cardiovascular events in SELECT participants
Semaglutide reduced major adverse cardiovascular events in SELECT participants with overweight or obesity and established cardiovascular disease without diabetes.
semaglutide: Semaglutide reduced body weight in adults with obesity or
Semaglutide reduced body weight in adults with obesity or overweight in randomized clinical-trial populations.
semaglutide: Semaglutide improved kidney outcomes in FLOW participants with type
Semaglutide improved kidney outcomes in FLOW participants with type 2 diabetes and chronic kidney disease.